Article

Synchronous Hyperactivity and Intercellular Calcium Waves in Astrocytes in Alzheimer Mice

Massachusetts General Hospital, Department of Neurology/Alzheimer's Disease Research Laboratory, 114 16th Street, Charlestown, MA 02129, USA.
Science (Impact Factor: 33.61). 03/2009; 323(5918):1211-5. DOI: 10.1126/science.1169096
Source: PubMed

ABSTRACT

Although senile plaques focally disrupt neuronal health, the functional response of astrocytes to Alzheimer's disease pathology is unknown. Using multiphoton fluorescence lifetime imaging microscopy in vivo, we quantitatively imaged astrocytic calcium homeostasis in a mouse model of Alzheimer's disease. Resting calcium was globally elevated in the astrocytic network, but was independent of proximity to individual plaques. Time-lapse imaging revealed that calcium transients in astrocytes were more frequent, synchronously coordinated across long distances, and uncoupled from neuronal activity. Furthermore, rare intercellular calcium waves were observed, but only in mice with amyloid-beta plaques, originating near plaques and spreading radially at least 200 micrometers. Thus, although neurotoxicity is observed near amyloid-beta deposits, there exists a more general astrocyte-based network response to focal pathology.

Download full-text

Full-text

Available from: Kishore V. Kuchibhotla, Jun 20, 2014
    • "The cell-specific contributions of purinergic signaling have been clarified by recent work on the functional role of the P2Y 1 R in glial cells, particularly astrocytes. In the APPswe/ PS1dE9 and APP þ PS1 mouse models of AD, multiphoton fluorescence lifetime in vivo imaging (FLIM) was utilized to demonstrate that astrocytic networks in the AD mouse brain have significantly higher resting[Ca 2þ ]i levels than in wild type animals and exhibited increased propagation of intercellular calcium waves near Ab plaques, which was suggested to contribute to Ab-induced neuronal damage and synapse loss (Kuchibhotla et al., 2009;Delekate et al., 2014). Furthermore, expression of the P2Y 1 R in the APP þ PS1 mouse brain was shown to be primarily localized to reactive astrocytes near Ab plaques and blockade of P2Y 1 R signaling using the selective antagonist MRS2179 abolished the astrocytic hyperactivity and reduced[Ca 2þ ]i and intercellular calcium waves (Delekate et al., 2014), suggesting that P2Y 1 R inhibition in astrocytes could be therapeutic in the treatment of AD. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Alzheimer's disease (AD) is a neurodegenerative disorder characterized by a progressive loss of memory and cognitive ability and is a serious cause of mortality. Many of the pathological characteristics associated with AD are revealed post-mortem, including amyloid-β plaque deposition, neurofibrillary tangles containing hyperphosphorylated tau proteins and neuronal loss in the hippocampus and cortex. Although several genetic mutations and risk factors have been associated with the disease, the causes remain poorly understood. Study of disease-initiating mechanisms and AD progression in humans is inherently difficult as most available tissue specimens are from late-stages of disease. Therefore, AD researchers rely on in vitro studies and the use of AD animal models where neuroinflammation has been shown to be a major characteristic of AD. Purinergic receptors are a diverse family of proteins consisting of P1 adenosine receptors and P2 nucleotide receptors for ATP, UTP and their metabolites. This family of receptors has been shown to regulate a wide range of physiological and pathophysiological processes, including neuroinflammation, and may contribute to the pathogenesis of neurodegenerative diseases like Parkinson's disease, multiple sclerosis and AD. Experimental evidence from human AD tissue has suggested that purinergic receptors may play a role in AD progression and studies using selective purinergic receptor agonists and antagonists in vitro and in AD animal models have demonstrated that purinergic receptors represent novel therapeutic targets for the treatment of AD.
    No preview · Article · Oct 2015 · Neuropharmacology
  • Source
    • "lammation may disturb normal neuronal functions and impede regeneration ( Kinouchi et al . , 2003 ; Menet et al . , 2003 ; Pekny et al . , 2014 ; Widestrand et al . , 2007 ; Wilhelmsson et al . , 2004 ) . It may therefore be necessary to study reactive astrocytes with and without IF at the functional level of intracellular cal - cium homeostasis ( Kuchibhotla et al . , 2009 ) , and their GABA - and glutamate - sensitivity or intracellular coupling ( Peters et al . , 2009 ) to disclose functions attributable to IFs ."
    [Show abstract] [Hide abstract]
    ABSTRACT: Reactive astrocytes with an increased expression of intermediate filament (IF) proteins Glial Fibrillary Acidic Protein (GFAP) and Vimentin (VIM) surround amyloid plaques in Alzheimer's disease (AD). The functional consequences of this upregulation are unclear. To identify molecular pathways coupled to IF regulation in reactive astrocytes, and to study the interaction with microglia, we examined WT and APPswe/PS1dE9 (AD) mice lacking either GFAP, or both VIM and GFAP, and determined the transcriptome of cortical astrocytes and microglia from 15- to 18-month-old mice. Genes involved in lysosomal degradation (including several cathepsins) and in inflammatory response (including Cxcl5, Tlr6, Tnf, Il1b) exhibited a higher AD-induced increase when GFAP, or VIM and GFAP, were absent. The expression of Aqp4 and Gja1 displayed the same pattern. The downregulation of neuronal support genes in astrocytes from AD mice was absent in GFAP/VIM null mice. In contrast, the absence of IFs did not affect the transcriptional alterations induced by AD in microglia, nor was the cortical plaque load altered. Visualizing astrocyte morphology in GFAP-eGFP mice showed no clear structural differences in GFAP/VIM null mice, but did show diminished interaction of astrocyte processes with plaques. Microglial proliferation increased similarly in all AD groups. In conclusion, absence of GFAP, or both GFAP and VIM, alters AD-induced changes in gene expression profile of astrocytes, showing a compensation of the decrease of neuronal support genes and a trend for a slightly higher inflammatory expression profile. However, this has no consequences for the development of plaque load, microglial proliferation, or microglial activation. © 2015 Wiley Periodicals, Inc. © 2015 Wiley Periodicals, Inc.
    Full-text · Article · Mar 2015 · Glia
    • "Reproduced with permission from (Verkhratsky et al., in press). AD animals (APP/PS1 mice carrying mutated genes for APP and PS1) revealed abnormally frequent [Ca 2+ ] i oscillations in reactive astrocytes associated with senile plaques: these abnormal Ca 2+ transients gave rise to aberrant Ca 2+ waves spreading through coupled astrocytes (Kuchibhotla et al., 2009). In another AD model, in mice expressing Swedish mutation of the APP gene, astrocytes showed higher frequency of spontaneous oscillations even before the appearance of amyloid plaques (Takano et al., 2007). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Astrocytes are fundamental for homoeostasis, defence and regeneration of the central nervous system. Loss of astroglial function and astroglial reactivity contribute to the ageing of the brain and to neurodegenerative diseases. Changes in astroglia in ageing and neurodegeneration are highly heterogeneous and region-specific. In animal models of Alzheimer's disease (AD) astrocytes undergo degeneration and atrophy at the early stages of pathological progression, which possibly may alter homeostatic reserve of the brain and contribute to early cognitive deficits. At the later stages of AD reactive astrocytes are associated with neurite plaques, the future commonly found in animal models and in human diseased tissue. In animal models of the AD reactive astrogliosis develops in some (e.g. in the hippocampus) but not in all regions of the brain. For instance, in entorhinal and prefrontal cortex astrocytes to not mount gliotic response to emerging β-amyloid deposits. This deficits in reactivity coincides with higher vulnerability of these regions to AD-type pathology. Astroglial morphology and function can be regulated through environmental stimulation and/or medication suggesting that astrocytes can be regarded as a target for therapies aimed at prevention and cure of neurodegenerative disorders. Copyright © 2015. Published by Elsevier Ltd.
    No preview · Article · Jan 2015 · Neuroscience
Show more

Similar Publications